Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL COMPOUNDING PHARMACY INDUSTRY
2.1 Summary about Compounding Pharmacy Industry
2.2 Compounding Pharmacy Market Trends
2.2.1 Compounding Pharmacy Production & Consumption Trends
2.2.2 Compounding Pharmacy Demand Structure Trends
2.3 Compounding Pharmacy Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Pharmaceutical ingredient alteration (PIA)
4.2.2 Pharmaceutical application alteration (PAA)
4.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
4.2.4 Pharmaceutical dosage alteration (PDA)
4.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Adult
4.3.2 Paediatric
4.3.3 Geriatric
4.3.4 Veterinary
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Pharmaceutical ingredient alteration (PIA)
5.2.2 Pharmaceutical application alteration (PAA)
5.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
5.2.4 Pharmaceutical dosage alteration (PDA)
5.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Adult
5.3.2 Paediatric
5.3.3 Geriatric
5.3.4 Veterinary
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Pharmaceutical ingredient alteration (PIA)
6.2.2 Pharmaceutical application alteration (PAA)
6.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
6.2.4 Pharmaceutical dosage alteration (PDA)
6.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Adult
6.3.2 Paediatric
6.3.3 Geriatric
6.3.4 Veterinary
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Pharmaceutical ingredient alteration (PIA)
7.2.2 Pharmaceutical application alteration (PAA)
7.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
7.2.4 Pharmaceutical dosage alteration (PDA)
7.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Adult
7.3.2 Paediatric
7.3.3 Geriatric
7.3.4 Veterinary
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Pharmaceutical ingredient alteration (PIA)
8.2.2 Pharmaceutical application alteration (PAA)
8.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
8.2.4 Pharmaceutical dosage alteration (PDA)
8.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Adult
8.3.2 Paediatric
8.3.3 Geriatric
8.3.4 Veterinary
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Pharmaceutical ingredient alteration (PIA)
9.2.2 Pharmaceutical application alteration (PAA)
9.2.3 Currently unavailable pharmaceutical manufacturing (CUPM)
9.2.4 Pharmaceutical dosage alteration (PDA)
9.2.5 Specialized animal pharmaceutical manufacturing (SAPM)
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Adult
9.3.2 Paediatric
9.3.3 Geriatric
9.3.4 Veterinary
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Fagron
10.1.2 Wedgewood Pharma
10.1.3 CAPS
10.1.4 Fresenius Kabi
10.1.5 PharMEDium Services
10.1.6 Cantrell Drug
10.1.7 Advanced Pharma
10.1.8 Doughertys Pharmacy
10.1.9 Institutional Pharmacy Solutions
10.1.10 Lorraines Pharmacy
10.1.11 Village Compounding Pharmacy
10.1.12 Triangle Compounding Pharmacy
10.1.13 Olympia Pharmacy
10.2 Compounding Pharmacy Sales Date of Major Players (2017-2020e)
10.2.1 Fagron
10.2.2 Wedgewood Pharma
10.2.3 CAPS
10.2.4 Fresenius Kabi
10.2.5 PharMEDium Services
10.2.6 Cantrell Drug
10.2.7 Advanced Pharma
10.2.8 Doughertys Pharmacy
10.2.9 Institutional Pharmacy Solutions
10.2.10 Lorraines Pharmacy
10.2.11 Village Compounding Pharmacy
10.2.12 Triangle Compounding Pharmacy
10.2.13 Olympia Pharmacy
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
